Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14118103 | 0.92 | NOD1 (0.50) | FOLH1NOD1GLP1RALBEPHX2 | |
| SCHEMBL24796107 | 0.89 | NOD1 (0.66) | NOD1GLP1REPHX2 | |
| SCHEMBL14852205 | 0.89 | NOD1 (0.66) | NOD1GLP1REPHX2 | |
| SCHEMBL7894607 | 0.89 | NOD1 (0.66) | NOD1GLP1REPHX2 | |
| SCHEMBL26190934 | 0.89 | NOD1 (0.66) | NOD1GLP1REPHX2 | |
| SCHEMBL18710730 | 0.88 | ALB (0.56) | FOLH1NOD1GLP1RALB | |
| SCHEMBL24558585 | 0.88 | GLP1R (0.54) | FOLH1NOD1GLP1RALBEPHX2 | |
| SCHEMBL21242702 | 0.88 | GLP1R (0.54) | FOLH1NOD1GLP1RALBEPHX2 | |
| SCHEMBL24558475 | 0.88 | GLP1R (0.54) | FOLH1NOD1GLP1RALBEPHX2 | |
| SCHEMBL21938093 | 0.88 | GLP1R (0.54) | FOLH1NOD1GLP1RALBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604555-B2 | GIP derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604555-B2 | GIP derivatives and uses thereof | GIPR, GLP1R, GPR119 | FOLH1 327/4885NOD1 2846/4885GLP1R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.